HCVプロテアーゼ
信号経路図
研究分野
- 阻害剤の選択性比較
- 溶解度
| カタログ番号 | 製品カタログ | 溶解度(25°C) | ||
|---|---|---|---|---|
| 水 | DMSO | アルコール | ||
| S1482 | Daclatasvir (BMS-790052) | <1 mg/mL | 148 mg/mL | 148 mg/mL |
| S1538 | Telaprevir (VX-950) | <1 mg/mL | 136 mg/mL | <1 mg/mL |
| S1480 | Lomibuvir (VX-222, VCH-222) | <1 mg/mL | 89 mg/mL | 89 mg/mL |
| S1183 | Danoprevir (ITMN-191) | <1 mg/mL | 144 mg/mL | 144 mg/mL |
| S7579 | Ledipasvir (GS5885) | <1 mg/mL | 100 mg/mL | 100 mg/mL |
- HCV Protease阻害剤(5)
| 製品コード | 製品説明 | 文献中の使用例 | お客様のフィードバック |
|---|---|---|---|
| S1482 |
Daclatasvir (BMS-790052)Daclatasvir (BMS-790052) は一流、高選択性の C型肝炎ウイルス（HCV）阻害剤、EC50 が9–50 pM. |
Sensitivity of PR63cc to the combinatory treatment with asunaprevir and daclatasvir. Huh7.5.1 cells infected with PR63cc or JFH1 at an MOI of 0.05 for 3 days were treated with either asunaprevir, daclatasvir or in combination for another 3 days. 40 nM asunaprevir and 0.05 nM daclatasvir, approximately the EC50 concentration of the each inhibitor for JFH1, were used. The antiviral efficiency of each compound was evaluated by quantifying the intracellular HCV RNA by RT-qPCR. Data were expressed as the percentage of mock treatment control. The error bars were calculated from two independent experiments. ns, P > 0.05. *, P < 0.05.
|
|
| S1538 |
Telaprevir (VX-950)Telaprevir（VX-950）は、Ｃ型肝炎ウイルス（HCV）NS3-4Aセリン・プロテアーゼ阻害剤で、IC50 が0.35 μMになる。 |
HCV replicon genotype 1b cells were passaged in the presence of G418 alone (medium 694 control) or G418 with miravirsen, SPC4729 (oligonucleotide negative control) or telaprevir for 28 days in fixed concentrations at a multiple (X) of the EC50 of miravirsen or telaprevir. Colony formation was assessed by staining surviving cells with crystal violet.
|
|
| S1480 |
Lomibuvir (VX-222, VCH-222)Lomibuvir (VX-222, VCH-222)は新型有効と選択の非核苷ポリメラーゼ阻害剤、C型肝炎ウイルス（HCV）RNA依存のRNAポリメラーゼを抑制する時、 IC50 が 0.94-1.2 μMになる. |
Genetic barriers of JTK-853, NNI-A, PF-868554, VX-222, PSI-6130, BMS-790052, and TMC435 for Con1. VX-222 and the other DAAs were treated at 1/3xEC90 for 17 days. |
|
| S1183 |
Danoprevir (ITMN-191)Danoprevir (ITMN-191)はB型肝炎ウイルス（HCV）のNS3/4Aプロティナーゼの模擬阻害剤、 IC50 が 0.2-3.5 nM. |
Effects of TNFα, etanercept, and danoprevir on HCV infection in HFLC. Cells (n=6 wells/condition) were treated with TNFα (20 ng/ml) ± etanercept (1 μg/ml), danoprevir (2 μM), or media control before and during infection with Jc1G. Secreted luciferase was measured 96 hours after the start of infection. Box-and-whiskers plot; whiskers represent minimum and maximum values. Values of p were calculated by one-way ANOVA. ***, p < 0.001; ****, p < 0.0001
|
|
| S7579 |
Ledipasvir (GS5885)Ledipasvir（GS5885）は1種のHCV NS5Aポリメラーゼ（polymerase）阻害剤で、C型肝炎ウイルス感染の治療に使用します。 |
| 製品コード | 製品説明 | 文献中の使用例 | お客様のフィードバック |
|---|---|---|---|
| S1482 |
Daclatasvir (BMS-790052)Daclatasvir (BMS-790052) は一流、高選択性の C型肝炎ウイルス（HCV）阻害剤、EC50 が9–50 pM. |
Sensitivity of PR63cc to the combinatory treatment with asunaprevir and daclatasvir. Huh7.5.1 cells infected with PR63cc or JFH1 at an MOI of 0.05 for 3 days were treated with either asunaprevir, daclatasvir or in combination for another 3 days. 40 nM asunaprevir and 0.05 nM daclatasvir, approximately the EC50 concentration of the each inhibitor for JFH1, were used. The antiviral efficiency of each compound was evaluated by quantifying the intracellular HCV RNA by RT-qPCR. Data were expressed as the percentage of mock treatment control. The error bars were calculated from two independent experiments. ns, P > 0.05. *, P < 0.05.
|
|
| S1538 |
Telaprevir (VX-950)Telaprevir（VX-950）は、Ｃ型肝炎ウイルス（HCV）NS3-4Aセリン・プロテアーゼ阻害剤で、IC50 が0.35 μMになる。 |
HCV replicon genotype 1b cells were passaged in the presence of G418 alone (medium 694 control) or G418 with miravirsen, SPC4729 (oligonucleotide negative control) or telaprevir for 28 days in fixed concentrations at a multiple (X) of the EC50 of miravirsen or telaprevir. Colony formation was assessed by staining surviving cells with crystal violet.
|
|
| S1480 |
Lomibuvir (VX-222, VCH-222)Lomibuvir (VX-222, VCH-222)は新型有効と選択の非核苷ポリメラーゼ阻害剤、C型肝炎ウイルス（HCV）RNA依存のRNAポリメラーゼを抑制する時、 IC50 が 0.94-1.2 μMになる. |
Genetic barriers of JTK-853, NNI-A, PF-868554, VX-222, PSI-6130, BMS-790052, and TMC435 for Con1. VX-222 and the other DAAs were treated at 1/3xEC90 for 17 days. |
|
| S1183 |
Danoprevir (ITMN-191)Danoprevir (ITMN-191)はB型肝炎ウイルス（HCV）のNS3/4Aプロティナーゼの模擬阻害剤、 IC50 が 0.2-3.5 nM. |
Effects of TNFα, etanercept, and danoprevir on HCV infection in HFLC. Cells (n=6 wells/condition) were treated with TNFα (20 ng/ml) ± etanercept (1 μg/ml), danoprevir (2 μM), or media control before and during infection with Jc1G. Secreted luciferase was measured 96 hours after the start of infection. Box-and-whiskers plot; whiskers represent minimum and maximum values. Values of p were calculated by one-way ANOVA. ***, p < 0.001; ****, p < 0.0001
|
|
| S7579 |
Ledipasvir (GS5885)Ledipasvir（GS5885）は1種のHCV NS5Aポリメラーゼ（polymerase）阻害剤で、C型肝炎ウイルス感染の治療に使用します。 |
